Encompass Health (EHC) to Release Earnings on Wednesday

Encompass Health (NYSE:EHC) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, April 24th. Analysts expect the company to announce earnings of $0.93 per share for the quarter. Encompass Health has set its FY24 guidance at $3.77-$4.06 EPS and its FY 2024 guidance at 3.770-4.060 EPS.Parties interested in listening to the company’s conference call can do so using this link.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.12. The firm had revenue of $1.25 billion during the quarter, compared to the consensus estimate of $1.24 billion. Encompass Health had a net margin of 7.33% and a return on equity of 17.69%. On average, analysts expect Encompass Health to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Encompass Health Trading Down 0.9 %

NYSE:EHC opened at $79.98 on Wednesday. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.28 and a quick ratio of 1.28. The firm has a market capitalization of $8.01 billion, a price-to-earnings ratio of 23.05, a price-to-earnings-growth ratio of 1.49 and a beta of 0.94. Encompass Health has a one year low of $57.55 and a one year high of $83.73. The business has a fifty day moving average price of $77.01 and a 200-day moving average price of $70.09.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were paid a $0.15 dividend. The ex-dividend date was Thursday, March 28th. This represents a $0.60 annualized dividend and a dividend yield of 0.75%. Encompass Health’s dividend payout ratio (DPR) is 17.29%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Encompass Health by 6.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 75,622 shares of the company’s stock valued at $5,046,000 after purchasing an additional 4,796 shares during the last quarter. Public Employees Retirement System of Ohio boosted its holdings in shares of Encompass Health by 3.0% during the 4th quarter. Public Employees Retirement System of Ohio now owns 49,107 shares of the company’s stock valued at $3,276,000 after purchasing an additional 1,434 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Encompass Health by 8.6% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 10,048 shares of the company’s stock valued at $670,000 after purchasing an additional 795 shares during the last quarter. Barclays PLC lifted its holdings in shares of Encompass Health by 73.9% in the 4th quarter. Barclays PLC now owns 99,045 shares of the company’s stock valued at $6,609,000 after acquiring an additional 42,101 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Encompass Health by 4.7% in the 4th quarter. Vanguard Group Inc. now owns 9,997,034 shares of the company’s stock valued at $667,002,000 after acquiring an additional 450,081 shares during the last quarter. Institutional investors own 97.25% of the company’s stock.

Analyst Ratings Changes

EHC has been the subject of several analyst reports. Barclays upped their price objective on Encompass Health from $95.00 to $101.00 and gave the stock an “overweight” rating in a research note on Thursday, March 28th. Royal Bank of Canada restated an “outperform” rating and issued a $83.00 price objective on shares of Encompass Health in a research note on Friday, February 9th. William Blair restated an “outperform” rating on shares of Encompass Health in a research note on Wednesday, February 7th. Mizuho increased their price target on Encompass Health from $77.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, February 9th. Finally, Truist Financial increased their price target on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Friday, February 9th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $83.22.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.